Treatment of canine cutaneous epitheliotropic T‐cell lymphoma with oclacitinib: a case report
Jeylan Aslan, Michael A. Shipstone, Louise M. Sullivan
Abstract
Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.
Topics & Concepts
MedicineDermatologyLymphomaT-cell lymphomaCutaneous T-cell lymphomaCutaneous lymphomaComplete remissionInternal medicineChemotherapyMycosis fungoidesVeterinary Oncology ResearchInfectious Diseases and MycologyCutaneous lymphoproliferative disorders research